Since, we selected an anti-CD137 antibody that is not agonistic, the bispecific antibody will not induce CD137 signaling in HRS cells which would be expected to (1) enhance HRS cell proliferation, and (2) induce IL-13 secretion which may deviate a protective immune response toward a tumor-supporting Th2 response (15). Here, TNFRSF9 is linked to neoplasm.